During the past decade, AMAG Pharmaceuticals, Inc. conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 5 clinical trials were completed, i.e. on average, 500% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "AMAG Pharmaceuticals, Inc." are "Iron Deficiency Anemia" (5 trials) and "Nondialysis-dependent Chronic Kidney Disease" (1 trials). Many other conditions were trialed in "AMAG Pharmaceuticals, Inc." in a lesser frequency.

Most popular intervention types in "AMAG Pharmaceuticals, Inc." are "Drug" (5 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Ferumoxytol" (5 trials), "Oral Iron" (2 trials), "FCM" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "AMAG Pharmaceuticals, Inc." are 5 trials for "All" genders.

Currently, there are NaN active trials in "AMAG Pharmaceuticals, Inc.". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in AMAG Pharmaceuticals, Inc., undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in AMAG Pharmaceuticals, Inc., 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".